The immunology of tuberculosis: From bench to bedside

Respirology

Volumn 15, Issue 3, 2010, Pages 433-450

  Dheda, Keertan ^a,b,c,g   Schwander, Stephan K ^d   Zhu, Bingdong ^f   Van Zyl Smit, Richard N ^a   Zhang, Ying ^e  

^a Lung Infection and Immunity Unit   (Australia)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f LANZHOU UNIVERSITY   (China)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cytokine; Diagnostics; Immunology; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; ETANERCEPT; IMMUNOGLOBULIN; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE;

ADAPTIVE IMMUNITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; LIFE CYCLE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SERODIAGNOSIS; TUBERCULOSIS;

ANIMALS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOTHERAPY; LATENT TUBERCULOSIS; LIFE CYCLE STAGES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 77950262301     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01739.x     Document Type: Review

References (216)

1. World Health Organization. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. WHO, Geneva, 2009.
2. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO, Geneva, 2008.
3. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 2009 27 : 393 422.
4. Hanekom WA, Abel B, Scriba TJ. Immunological protection against tuberculosis. S. Afr. Med. J. 2007 97 : 973 977.
5. Reece ST, Kaufmann SH. Rational design of vaccines against tuberculosis directed by basic immunology. Int. J. Med. Microbiol. 2008 298 : 143 150.
6. Dietrich J, Doherty TM. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 2009 117 : 440 457.
7. Grotzke JE, Lewinsohn DM. Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect. 2005 7 : 776 788.
8. Dheda K, Smit RZ, Badri M et al. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr. Opin. Pulm. Med. 2009 15 : 188 200.
9. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev. Mol. Diagn. 2006 6 : 413 422.
10. Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009 33 : 956 973.
11. Barry CE 3rd., Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009 7 : 845 855.
12. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect. Dis. 2008 8 : 359 368.
13. Cobat A, Gallant CJ, Simkin L et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 2009 206 : 2583 2591.
14. Schwander SK, Torres M, Carranza CC et al. Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J. Immunol. 2000 165 : 1479 1485.
15. Carranza C, Juarez E, Torres M et al. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. Am. J. Respir. Crit. Care Med. 2006 173 : 238 245.
16. Pai M, Joshi R, Dogra S et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am. J. Respir. Crit. Care Med. 2006 174 : 349 355.
17. Ewer K, Millington KA, Deeks JJ et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 2006 174 : 831 839.
18. Hill PC, Brookes RH, Fox A et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007 4 : e192.
19. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol. 2009 17 : 183 188.
20. Pai M. Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat. Rev. Microbiol. 2010 8 : 242.
21. Schlesinger LS, Bellinger-Kawahara CG, Payne NR et al. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 1990 144 : 2771 2780.
22. Tailleux L, Pham-Thi N, Bergeron-Lafaurie A et al. DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis. PLoS Med. 2005 2 : e381.
23. Kang PB, Azad AK, Torrelles JB et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J. Exp. Med. 2005 202 : 987 999.
24. Hirsch CS, Ellner JJ, Russell DG et al. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J. Immunol. 1994 152 : 743 753.
25. Tailleux L, Schwartz O, Herrmann JL et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 2003 197 : 121 127.
26. Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 2003 197 : 7 17.
27. Schwander SK, Sada E, Torres M et al. T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. J. Infect. Dis. 1996 173 : 1267 1272.
28. Robinson DS, Ying S, Taylor IK et al. Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 1994 149 : 989 993.
29. Schwander SK, Torres M, Sada E et al. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. J. Infect. Dis. 1998 178 : 1434 1445.
30. Taha RA, Kotsimbos TC, Song YL et al. IFN-gamma and IL-12 are increased in active compared with inactive tuberculosis. Am. J. Respir. Crit. Care Med. 1997 155 : 1135 1139.
31. Herrera MT, Torres M, Nevels D et al. Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. Tuberculosis (Edinb) 2009 89 : 38 47.
32. Pieters J, Gatfield J. Hijacking the host: survival of pathogenic mycobacteria inside macrophages. Trends Microbiol. 2002 10 : 142 146.
33. Young D, Hussell T, Dougan G. Chronic bacterial infections: living with unwanted guests. Nat. Immunol. 2002 3 : 1026 1032.
34. Chua J, Vergne I, Master S et al. A tale of two lipids: Mycobacterium tuberculosis phagosome maturation arrest. Curr. Opin. Microbiol. 2004 7 : 71 7.
35. Dahl KE, Shiratsuchi H, Hamilton BD et al. Selective induction of transforming growth factor beta in human monocytes bylipoarabinomannan of Mycobacterium tuberculosis. Infect. Immun. 1996 64 : 399 405.
36. Hirsch CS, Hussain R, Toossi Z et al. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc. Natl. Acad. Sci. U.S.A. 1996 93 : 3193 3198.
37. Hirsch CS, Toossi Z, Othieno C et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J. Infect. Dis. 1999 180 : 2069 2073.
38. Almeida AS, Lago PM, Boechat N et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J. Immunol. 2009 183 : 718 731.
39. Kursar M, Koch M, Mittrucker HW et al. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 2007 178 : 2661 2665.
40. Guyot-Revol V, Innes JA, Hackforth S et al. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 2006 173 : 803 810.
41. Ribeiro-Rodrigues R, Resende Co T, Rojas R et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin. Exp. Immunol. 2006 144 : 25 34.
42. Daley CL, Small PM, Schecter GF et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N. Engl. J. Med. 1992 326 : 231 235.
43. Sonnenberg P, Murray J, Glynn JR et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001 358 : 1687 1693.
44. Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 1989 320 : 545 550.
45. Bocchino M, Sanduzzi A, Bariffi F. Mycobacterium tuberculosis and HIV co-infection in the lung: synergic immune dysregulation leading to disease progression. Monaldi Arch. Chest Dis. 2000 55 : 381 388.
46. Collins KR, Mayanja-Kizza H, Sullivan BA et al. Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. J. Acquir. Immune Defic. Syndr. 2000 24 : 408 417.
47. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001 345 : 1098 1104.
48. Wallis RS, Broder M, Wong J et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 2004 39 : 1254 1255.
49. Wallis RS. Mycobacterial disease attributable to tumor necrosis factor-alpha blockers. Clin. Infect. Dis. 2008 47 : 1603 1605, author reply 5-6.
50. de Jong R, Altare F, Haagen IA et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998 280 : 1435 1438.
51. Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998 280 : 1432 1435.
52. Jouanguy E, Lamhamedi-Cherradi S, Lammas D et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 1999 21 : 370 378.
53. Newport MJ, Huxley CM, Huston S et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 1996 335 : 1941 1949.
54. Altare F, Jouanguy E, Lamhamedi-Cherradi S et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am. J. Hum. Genet. 1998 62 : 723 726.
55. Garton NJ, Waddell SJ, Sherratt AL et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 2008 5 : e75.
56. Russell DG, Cardona PJ, Kim MJ et al. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 2009 10 : 943 948.
57. Dheda K, Booth H, Huggett JF et al. Lung remodeling in pulmonary tuberculosis. J. Infect. Dis. 2005 192 : 1201 1209.
58. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007 7 : 179 190.
59. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 1998 66 : 1277 1281.
60. Ferguson JS, Martin JL, Azad AK et al. Surfactant protein D increases fusion of Mycobacterium tuberculosis-containing phagosomes with lysosomes in human macrophages. Infect. Immun. 2006 74 : 7005 7009.
61. Divangahi M, Mostowy S, Coulombe F et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J. Immunol. 2008 181 : 7157 7165.
62. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 2008 10 : 995 1004.
63. Liu PT, Modlin RL. Human macrophage host defense against Mycobacterium tuberculosis. Curr. Opin. Immunol. 2008 20 : 371 376.
64. Pathak SK, Basu S, Basu KK et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat. Immunol. 2007 8 : 610 618.
65. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin d-mediated human antimicrobial response. Science 2006 311 : 1770 1773.
66. Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. Nutr. Rev. 2009 67 : 289 293.
67. Mendez-Samperio P. Role of antimicrobial peptides in host defense against mycobacterial infections. Peptides 2008 29 : 1836 1841.
68. Liu PT, Stenger S, Tang DH et al. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007 179 : 2060 2063.
69. Yang CS, Shin DM, Kim KH et al. NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression. J. Immunol. 2009 182 : 3696 3705.
70. Bellamy RJ, Hill AV. Host genetic susceptibility to human tuberculosis. Novartis Found. Symp. 1998 217 : 3 13, discussion -23.
71. Thuong NT, Hawn TR, Thwaites GE et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun. 2007 8 : 422 428.
72. Verreck FA, de Boer T, Langenberg DM et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. U.S.A. 2004 101 : 4560 4565.
73. Savage ND, de Boer T, Walburg KV et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 2008 181 : 2220 2226.
74. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 2001 1 : 20 30.
75. MacMicking JD, North RJ, LaCourse R et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 1997 94 : 5243 5248.
76. Gutierrez MG, Master SS, Singh SB et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004 119 : 753 766.
77. Alonso S, Pethe K, Russell DG et al. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc. Natl. Acad. Sci. U.S.A. 2007 104 : 6031 6036.
78. Singh SB, Davis AS, Taylor GA et al. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006 313 : 1438 1441.
79. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003 302 : 654 659.
80. Harris J, De Haro SA, Master SS et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007 27 : 505 517.
81. Flynn J, Chan J. Tuberculosis: latency and reactivation. Infect. Immun. 2001 69 : 4195 4201.
82. Bruns H, Meinken C, Schauenberg P et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest. 2009 119 : 1167 1177.
83. Sada-Ovalle I, Chiba A, Gonzales A et al. Innate invariant NKT cells recognize mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog. 2008 4 : e1000239.
84. Millman AC, Salman M, Dayaram YK et al. Natural killer cells, glutathione, cytokines, and innate immunity against Mycobacterium tuberculosis. J. Interferon Cytokine Res. 2008 28 : 153 165.
85. Mars LT, Araujo L, Kerschen P et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl. Acad. Sci. U.S.A. 2009 106 : 6238 6243.
86. Martineau AR, Newton SM, Wilkinson KA et al. Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 2007 117 : 1988 1994.
87. Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009 30 : 538 546.
88. Persson YAZ, Blomgran-Julinder R, Rahman S et al. Mycobacterium tuberculosis-induced apoptotic neutrophils trigger a pro-inflammatory response in macrophages through release of heat shock protein 72, acting in synergy with the bacteria. Microbes Infect. 2008 10 : 233 240.
89. Dannenberg AM. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model. ASM Press, Washington, DC. 2006.
90. Carlos D, Frantz FG, Souza-Junior DA et al. TLR2-dependent mast cell activation contributes to the control of Mycobacterium tuberculosis infection. Microbes Infect. 2009 11 : 770 778.
91. Casetti R, Martino A. The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol. Immunol. 2008 5 : 161 170.
92. Martino A, Casetti R, Sacchi A et al. Central memory V gamma 9V delta 2 T lymphocytes primed and expanded by bacillus Calmette-Guerin-Infected dendritic cells kill mycobacterial-infected monocytes. J. Immunol. 2007 179 : 3057 3064.
93. Martin B, Hirota K, Cua DJ et al. Interleukin-17-producing [gamma][delta] T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009 31 : 321 330.
94. Khader SA, Partida-Sanchez S, Bell G et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 2006 203 : 1805 1815.
95. Schaible UE, Winau F, Sieling PA et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 2003 9 : 1039 1046.
96. Ngai P, McCormick S, Small C et al. Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect. Immun. 2007 75 : 2244 2252.
97. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 2005 11 : S33 44.
98. Wang J, Santosuosso M, Ngai P et al. Activation of CD8 T cells by mycobacterial vaccination protects against pulmonary tuberculosis in the absence of CD4 T cells. J. Immunol. 2004 173 : 4590 4597.
99. Kaufmann SHE, Parida SK. Tuberculosis. in Africa: learning from pathogenesis for biomarker identification. Cell Host. Microbe. 2008 4 : 219 228.
100. Dorhoi A, Kaufmann SHE. Fine-tuning of T cell responses during infection. Curr. Opin. Immunol. 2009 21 : 367 377.
101. Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J. Exp. Med. 2001 194 : F53 7.
102. Joosten SA, Ottenhoff TH. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum. Immunol. 2008 69 : 760 770.
103. Scott-Browne JP, Shafiani S, Tucker-Heard G et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 2007 204 : 2159 2169.
104. Li L, Wu CY. CD4(+)CD25(+) Treg cells inhibit human memory gamma delta T cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6. Blood 2008 111 : 5629 5636.
105. Gong G, Shao L, Wang Y et al. Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood 2009 113 : 837 845.
106. Sharma PK, Saha PK, Singh A et al. FoxP3(+) regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am. J. Respir. Crit. Care Med. 2009 179 : 1061 1070.
107. Rahman S, Gudetta B, Fink J et al. Compartmentalization of immune responses in human tuberculosis few CD8 + effector t cells but elevated levels of FbxP3 + regulatory T cells in the granulomatous lesions. Am. J. Pathol. 2009 174 : 2211 2224.
108. Chiacchio T, Casetti R, Butera O et al. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. Clin. Exp. Immunol. 2009 156 : 463 470.
109. Jaron B, Maranghi E, Leclerc C et al. Effect of attenuation of treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE 2008 3 : e2833.
110. Bayry J, Tchilian EZ, Davies MN et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc. Natl. Acad. Sci. U.S.A. 2008 105 : 10221 10226.
111. Bettelli E, Carrier YJ, Gao WD et al. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 2006 441 : 235 238.
112. Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 2009 157 : 235 243.
113. Maglione PJ, Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 2009 39 : 676 686.
114. Carroll MV, Lack N, Sim E et al. Multiple routes of complement activation by Mycobacterium bovis BCG. Mol. Immunol. 2009 46 : 3367 3378.
115. Lindenstrom T, Agger EM, Korsholm KS et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 2009 182 : 8047 8055.
116. Rook GA, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J. Infect. Dis. 2007 196 : 191 198.
117. Rook GA, Dheda K, Zumla A. Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb) 2006 86 : 152 162.
118. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 2005 5 : 661 667.
119. Johnson JL, Ssekasanvu E, Okwera A et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2003 168 : 185 191.
120. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N et al. Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 2004 4 : 44.
121. Koh WJ, Kwon OJ, Suh GY et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci. 2004 19 : 167 171.
122. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J. Infect. Dis. 2005 191 : 856 865.
123. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1995 1 : 384 397.
124. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004 18 : 257 264.
125. Churchyard GJ, Kaplan G, Fallows D et al. Advances in Immunotherapy for tuberculosis treatment. Clin. Chest Med. 2009 30 : 769 782.
126. World Health Organization. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. Geneva, 29-31 January 2007. [Accessed October 2009.] Available from URL: http://apps.who.int/tdr/svc/ publications/tdr-research-publications/immunotherapeutic-interventions-tb
127. Zuany-Amorim C, Sawicka E, Manlius C et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 2002 8 : 625 629.
128. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group. Lancet 1999 354 : 116 119.
129. Johnson JL, Kamya RM, Okwera A et al. Randomized controlled trial of Mycobacterium vaccaeimmunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 2000 181 : 1304 1312.
130. Mwinga A, Nunn A, Ngwira B et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002 360 : 1050 1055.
131. Fan MCX, Wang K, Mao H et al. Adjuvant effect of Mycobacterium vaccae on treatment of recurrent treated pulmonary tuberculosis: a meta-analysis. Chin. J. Evid. Based Med. 2007 7 : 449 455.
132. von Reyn CF, Arbeit RD, Mtei L et al. [PS- 81689-20] The DarDar prime-boost TB vaccine trial in HIV infection: final results. Int. J. Tuberc. Lung Dis. 2008 12 : S318.
133. Roy E, Stavropoulos E, Brennan J et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect. Immun. 2005 73 : 6101 6109.
134. Nikolaeva LG, Maystat TV, Pylypchuk VS et al. Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin. Cytokine 2008 44 : 392 396.
135. Nikolaeva LG, Maystat TV, Pylypchuk VS et al. Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. Int. Immunopharmacol. 2008 8 : 845 851.
136. Prihoda ND, Arjanova OV, Yurchenko LV et al. Adjunct immunotherapy of tuberculosis in drug-resistant TB and TB/HIV co-infected patients. Int. J. Biomed. Pharm. Sci. 2008 2 : 59 64.
137. Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J. Indian Med. Assoc. 2002 100 : 191 193.
138. Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999 400 : 269 271.
139. Stickney DR, Noveljic Z, Garsd A et al. Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. Antimicrob. Agents Chemother. 2007 51 : 2639 2641.
140. Cardona PJ, Amat I, Gordillo S et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005 23 : 1393 1398.
141. Davies GR, Khoo SH, Aarons LJ. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J. Antimicrob. Chemother. 2006 58 : 594 600.
142. Biglino A, Crivelli P, Concialdi E et al. Clinical usefulness of ELISPOT assay on pericardial fluid in a case of suspected tuberculous pericarditis. Infection 2008 36 : 601 604.
143. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 1993 147 : 1062 1063.
144. Wallis RS, Doherty TM, Onyebujoh P et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 2009 9 : 162 172.
145. Doherty M, Wallis RS, Zumla A. et al. Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulm. Med. 2009 15 : 181 187. 10.1097/MCP.0b013e328326f42c.
146. Talat N, Shahid F, Dawood G et al. Changes in biomarker profiles associated with clinical and subclinical tuberculosis in a high transmission setting: a four-year follow-up study. Scand. J. Immunol. 2009 69 : 537 546.
147. Aiken AM, Hill PC, Fox A et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect. Dis. 2006 6 : 66.
148. Goletti D, Carrara S, Mayanja-Kizza H et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 2008 8 : 11.
149. Carrara S, Vincenti D, Petrosillo N et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin. Infect. Dis. 2004 38 : 754 756.
150. Siawaya JF, Bapela NB, Ronacher K et al. Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin. Vaccine Immunol. 2008 15 : 1165 1170.
151. Pai M, Joshi R, Bandyopadhyay M et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 2007 35 : 98 103.
152. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008 13 : 468 472.
153. van Zyl-Smit RN, Pai M, Peprah K et al. Within-subject variability and boosting of T cell IFN-{gamma} responses following tuberculin skin testing. Am. J. Respir. Crit. Care Med. 2009 180 : 49 58.
154. Wu B, Huang C, Kato-Maeda M et al. Messenger RNA expression of IL-8, FOXP3, and IL-12beta differentiates latent tuberculosis infection from disease. J. Immunol. 2007 178 : 3688 3694.
155. Veenstra H, Baumann R, Carroll NM et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin. Exp. Immunol. 2006 145 : 252 260.
156. Mukae H, Ashitani J, Tokojima M et al. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology 2003 8 : 326 331.
157. Tsao TC, Hong J, Li LF et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000 117 : 103 109.
158. Immanuel C, Rajeswari R, Rahman F et al. Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. Int. J. Tuberc. Lung Dis. 2001 5 : 185 190.
159. Bajaj G, Rattan A, Ahmad P. Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr. 1989 26 : 1010 1013.
160. Djoba Siawaya JF, Chegou NN, van den Heuvel MM et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 2009 47 : 132 136.
161. Chegou NN, Black GF, Kidd M et al. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm. Med. 2009 9 : 21.
162. Djoba Siawaya JF, Beyers N, van Helden P et al. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin. Exp. Immunol. 2009 156 : 69 77.
163. Torres M, Herrera T, Villareal H et al. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect. Immun. 1998 66 : 176 180.
164. Demissie A, Ravn P, Olobo J et al. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect. Immun. 1999 67 : 5967 5971.
165. Vekemans J, Lienhardt C, Sillah JS et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect. Immun. 2001 69 : 6554 6557.
166. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 2005 3 : 656 662.
167. Lotte A, Wasz-Hockert O, Poisson N et al. A bibliography of the complications of BCG vaccination. A comprehensive list of the world literature since the introduction of BCG up to July 1982, supplemented by over 100 personal communications. Adv. Tuberc. Res. 1984 21 : 194 245.
168. Hesseling AC, Cotton MF, Fordham RC et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int. J. Tuberc. Lung Dis. 2008 12 : 1376 1379.
169. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999 284 : 1520 1523.
170. Rieder HL. BCG vaccination. In : Davies P, Barnes P, Gordon S (eds.) Clinical Tuberculosis Fourth Edition, Hodder Arnold, London, 2008 411 427.
171. Fine PE, Floyd S, Stanford JL et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol. Infect. 2001 126 : 379 387.
172. Fine PE. BCG: the challenge continues. Scand. J. Infect. Dis. 2001 33 : 243 245.
173. Elias D, Britton S, Aseffa A et al. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine 2008 26 : 3897 3902.
174. Elias D, Wolday D, Akuffo H et al. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin. Exp. Immunol. 2001 123 : 219 225.
175. Resende CT, Hirsch CS, Toossi Z et al. Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy. Clin. Exp. Immunol. 2007 147 : 219 225.
176. Malhotra I, Mungai P, Wamachi A et al. Helminth- and Bacillus
177. Guwatudde D, Nakakeeto M, Jones-Lopez EC et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am. J. Epidemiol. 2003 158 : 887 898.
178. Soysal A, Millington KA, Bakir M et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005 366 : 1443 1451.
179. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly. Epidemiol. Rec. 2007 82 : 193 196.
180. Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 2005 115 : 2472 2479.
181. Horwitz MA, Harth G, Dillon BJ et al. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U.S.A. 2000 97 : 13853 13858.
182. Horwitz MA, Harth G, Dillon BJ et al. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect. Immun. 2005 73 : 4676 4683.
183. Hess J, Miko D, Catic A et al. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. U.S.A. 1998 95 : 5299 5304.
184. Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009 27 : 4412 4423.
185. Ibanga HB, Brookes RH, Hill PC et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect. Dis. 2006 6 : 522 528.
186. McShane H, Pathan AA, Sander CR et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005 85 : 47 52.
187. Dietrich J, Aagaard C, Leah R et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 2005 174 : 6332 6339.
188. Barker LF, Brennan MJ, Rosenstein PK et al. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol. 2009 21 : 331 338.
189. Mansoor N, Scriba TJ, de Kock M et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J. Infect. Dis. 2009 199 : 982 990.
190. Tristao-Sa R, Ribeiro-Rodrigues R, Johnson LT et al. Intestinal nematodes and pulmonary tuberculosis. Rev. Soc. Bras. Med. Trop. 2002 35 : 533 535.
191. Soares AP, Scriba TJ, Joseph S et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 2008 180 : 3569 3577.
192. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008 8 : 247 258.
193. Sarrazin H, Wilkinson KA, Andersson J et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J. Infect. Dis. 2009 199 : 702 710.
194. Vukmanovic-Stejic M, Agius E, Booth N et al. The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J. Clin. Invest. 2008 118 : 3639 3650.
195. Dheda K, Udwadia ZF, Huggett JF et al. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr. Opin. Pulm. Med. 2005 11 : 195 202.
196. Cosmi L, Maggi L, Santarlasci V et al. Detection by flow cytometry of ESAT-6- and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosis. Int. Arch. Allergy Immunol. 2007 143 : 1 9.
197. Hougardy JM, Schepers K, Place S et al. Heparin-binding-hemagglutinin- induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS ONE 2007 2 : e926.
198. Jafari C, Thijsen S, Sotgiu G et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a tuberculosis network European trialsgroup study. Am. J. Respir. Crit. Care Med. 2009 180 : 666 673.
199. Dheda K, van Zyl-Smit RN, Meldau R et al. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax 2009 64 : 847 853.
200. Cashmore T, van Zyl-Smit RN, Dheda K et al. Feasibility and diagnostic utility of antigen-specific ifn-γ responses for the rapid immunodiagnosis of tb using induced sputum. (Abstract) 2nd International IGRA Symposium, Dubrovnik 2009.
201. Dheda K, van Zyl-Smit RN, Sechi LA et al. Utility of quantitative T cell responses versus unstimulated IFN-{gamma} for the diagnosis of pleural tuberculosis. Eur. Respir. J. 2009 34 : 1118 1126.
202. Thomas MM, Hinks TS, Raghuraman S et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int. J. Tuberc. Lung Dis. 2008 12 : 651 657.
203. Kosters K, Nau R, Bossink A et al. Rapid diagnosis of CNS tuberculosis by a T-cell interferon-gamma release assay on cerebrospinal fluid mononuclear cells. Infection 2008 36 : 597 600.
204. Kim SH, Chu K, Choi SJ et al. Diagnosis of central nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin. Vaccine Immunol. 2008 15 : 1356 1362.
205. van Zyl-Smit RN, Patel V, Dheda K et al. Rapid site-specific immunodiagnosis of tuberculosis: is it useful in clinical practice in South Africa? (Abstract) 2nd International IGRA Symposium, Dubrovnik 2009.
206. Kim S-H, Cho O-H, Park SJ et al. Diagnosis of abdominal tuberculosis by T-cell-based assays on peripheral blood and peritoneal fluid mononuclear cells. J. Infect. 2009 59 : 409 415.
207. Tinelli A, Malvasi A, Vergara D et al. Abdominopelvic tuberculosis in gynaecology: laparoscopical and new laboratory findings. Aust. N. Z. J. Obstet. Gynaecol. 2008 48 : 90 5.
208. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 1978 117 : 621 624.
209. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull. Int. Union Tuberc. 1975 50 : 90 106.
210. Mazurek GH, Jereb J, Lobue P et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep. 2005 54 : 49 55.
211. Baba K, Sornes S, Hoosen AA et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect. Dis. 2008 8 : 35.
212. Chegou NN, Walzl G, Bolliger CT et al. Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis. Respiration 2008 76 : 131 138.
213. Losi M, Bossink A, Codecasa L et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur. Respir. J. 2007 30 : 1173 1179.
214. Patel V, Singh R, Connolly C et al. Cerebrospinal T cell responses aid the diagnosis of tuberculous meningitis in a HIV and TB endemic population. AJRCCM 2010 (in press).
215. Locht C, Hougardy JM, Rouanet C et al. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 2006 86 : 303 309.
216. Ruhwald M, Bjerregaard-Andersen M, Rabna P et al. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res. Notes 2009 2 : 19.